Neose gets undisclosed milestone from Novo Nordisk under Factor IX accord
Neose Technologies has received a milestone payment from Danish diabetes giant Novo Nordisk under their November 2003 license agreement for the use of the US firm's GlycoPEGylation technology to develop a next-generation version of Factor IX. The agent is used in the treatment of hemophilia B, which is caused by a deficiency of this blood plasma protein that affects the clotting property of blood. The company is also working with Novo Nordisk under separate license deals to develop GlycoPEGylated versions of recombinant Factors VIIa and VIII. A Phase I trial of GlycoPEG-Factor VIIa is currently ongoing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze